I-Mab (IMAB) Competitors $3.79 +0.14 (+3.84%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$3.81 +0.02 (+0.55%) As of 09/19/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMAB vs. SDGR, HROW, AMPH, NUVB, WVE, ETNB, TLRY, PGEN, RCUS, and NTLAShould you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include Schrodinger (SDGR), Harrow (HROW), Amphastar Pharmaceuticals (AMPH), Nuvation Bio (NUVB), WAVE Life Sciences (WVE), 89BIO (ETNB), Tilray Brands (TLRY), Precigen (PGEN), Arcus Biosciences (RCUS), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. I-Mab vs. Its Competitors Schrodinger Harrow Amphastar Pharmaceuticals Nuvation Bio WAVE Life Sciences 89BIO Tilray Brands Precigen Arcus Biosciences Intellia Therapeutics I-Mab (NASDAQ:IMAB) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings. Is IMAB or SDGR more profitable? I-Mab has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. I-Mab's return on equity of -19.65% beat Schrodinger's return on equity.Company Net Margins Return on Equity Return on Assets I-MabN/A -19.65% -18.58% Schrodinger -76.22%-45.70%-24.81% Which has higher valuation and earnings, IMAB or SDGR? I-Mab has higher earnings, but lower revenue than Schrodinger. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioI-Mab$3.89M79.56-$22.23MN/AN/ASchrodinger$207.54M6.90-$187.12M-$2.48-7.84 Do institutionals and insiders have more ownership in IMAB or SDGR? 38.4% of I-Mab shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 21.0% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, IMAB or SDGR? I-Mab has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Do analysts rate IMAB or SDGR? I-Mab presently has a consensus target price of $7.00, indicating a potential upside of 84.70%. Schrodinger has a consensus target price of $27.83, indicating a potential upside of 43.10%. Given I-Mab's stronger consensus rating and higher probable upside, analysts clearly believe I-Mab is more favorable than Schrodinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score I-Mab 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Schrodinger 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media refer more to IMAB or SDGR? In the previous week, Schrodinger had 2 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Schrodinger and 1 mentions for I-Mab. Schrodinger's average media sentiment score of 1.76 beat I-Mab's score of -0.21 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Schrodinger 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryI-Mab beats Schrodinger on 8 of the 13 factors compared between the two stocks. Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAB vs. The Competition Export to ExcelMetricI-MabMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$298.06M$3.16B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E RatioN/A20.6576.6126.78Price / Sales79.56446.54532.08124.24Price / CashN/A46.0037.9261.55Price / Book1.539.6613.746.40Net Income-$22.23M-$53.02M$3.30B$271.71M7 Day Performance-7.33%3.11%2.65%3.47%1 Month Performance-16.15%7.56%6.04%9.90%1 Year Performance250.93%11.15%80.14%28.50% I-Mab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMABI-Mab2.4001 of 5 stars$3.79+3.8%$7.00+84.7%+241.4%$298.06M$3.89M0.00380Analyst DowngradeSDGRSchrodinger3.4542 of 5 stars$19.44+1.6%$27.83+43.2%-6.7%$1.41B$207.54M-7.84790Positive NewsHROWHarrow2.8529 of 5 stars$39.77+7.5%$64.67+62.6%-4.6%$1.37B$199.61M-159.08180AMPHAmphastar Pharmaceuticals4.0518 of 5 stars$29.26-0.5%$31.60+8.0%-44.8%$1.37B$731.97M10.962,028Positive NewsNUVBNuvation Bio3.0155 of 5 stars$3.48-10.9%$7.50+115.8%+8.8%$1.33B$7.87M-5.5260News CoverageAnalyst ForecastHigh Trading VolumeWVEWAVE Life Sciences4.3714 of 5 stars$7.58-8.6%$20.33+168.2%+16.0%$1.32B$108.30M-8.42240ETNB89BIO2.3408 of 5 stars$8.57-3.4%$28.00+226.7%+79.4%$1.32BN/A-2.3740Trending NewsAnalyst DowngradeTLRYTilray Brands2.8562 of 5 stars$1.12-5.9%$1.94+73.0%-32.0%$1.31B$821.31M-0.482,842PGENPrecigen4.4344 of 5 stars$4.16-4.6%$8.25+98.3%+250.5%$1.30B$4.34M-9.90190Insider TradeRCUSArcus Biosciences1.9443 of 5 stars$11.43-6.3%$21.14+85.0%-26.1%$1.30B$258M-3.60500Positive NewsNTLAIntellia Therapeutics4.46 of 5 stars$11.84-1.8%$29.05+145.4%-32.0%$1.29B$57.88M-2.52600Trending NewsAnalyst ForecastOptions Volume Related Companies and Tools Related Companies Schrodinger Alternatives Harrow Alternatives Amphastar Pharmaceuticals Alternatives Nuvation Bio Alternatives WAVE Life Sciences Alternatives 89BIO Alternatives Tilray Brands Alternatives Precigen Alternatives Arcus Biosciences Alternatives Intellia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAB) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
